Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Inmune Bio Q3 2026 Results: Net Loss of $4.72M, Loss Narrows

For the nine months ended September 30, 2026, INmune Bio reported a net loss of $11.4 million, a significant reduction from the $40.7 million loss in the prior year period which included a $16.5 million impairment charge. The company reported zero revenue for the 2026 period and expressed substantial doubt about its ability to continue as a going concern due to insufficient liquidity to sustain operations for the next twelve months.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-4.7-6.5
EPS (diluted, $ a share)$-0.17$-0.24

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: INMB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Inmune Bio, Inc.: key numbers

Share price
$0.9464Close, Nov 16
Market cap
$29.3M
Shares outstanding
30.96MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Inmune Bio, Inc.

All →
7:41 AM ET 8-K
Capital Raise

Inmune Bio Capital Raise of $4.5M

INmune Bio Inc. entered into a securities purchase agreement with a single institutional investor for a $4.5 million registered direct offering and concurrent private placement. The company is issuing 3,000,000 shares of common stock at $1.50 per share along with warrants to purchase an additional 3,000,000 shares at an exercise price of $1.65. Proceeds are intended for working capital and general corporate purposes.

Value
$4.5M
9:01 AM ET 8-K
Investor Presentation

Inmune Bio Investor Presentation

INmune Bio filed a formal investor presentation deck and announced a Master Services Agreement with Uniphar to establish a commercialization framework for Ebstrocel. The partnership will initially focus on named-patient access in Europe and the MENA region, providing a capital-efficient infrastructure for international distribution. Additionally, the company submitted a pre-Marketing Authorisation Application to the UK MHRA for Ebstrocel.

Counterparty
Uniphar Durbin Ireland Limited
4:06 PM ET 8-K
Leadership Change

Inmune Bio Leadership Change

INmune Bio, Inc. has expanded its Board of Directors to seven members and appointed R. Duane Clark II and James Sapirstein as independent directors. Mr. Clark currently leads Sanofi's U.S. Rare Diseases business, while Mr. Sapirstein is the CEO of Cocrystal Pharma and has extensive experience in biopharma business development and licensing. These appointments are intended to strengthen the company's commercialization planning for Ebstrocel and its strategic partnering capabilities.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.